Membrane-permeant peptide complexes for treatment of sepsis

Details Membrane-permeant peptide complexes for treatment of sepsis Membrane-permeant peptide complexes for treatment of sepsis

2005-11-23

2011-10-18

Jones, D L (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001110, C424S001650, C514S001100, C514S001400

Reexamination Certificate

active

08038984

ABSTRACT:
Methods and compositions for treating sepsis using cell membrane-permeant peptide conjugate covalent compounds having target cell specificity are provided.

REFERENCES:
patent: 4452774 (1984-06-01), Jones et al.
patent: 4526714 (1985-07-01), Feijen et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4988496 (1991-01-01), Srinivzsen et al.
patent: 5135736 (1992-08-01), Anderson et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5403574 (1995-04-01), Piwnica-Worms
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5670133 (1997-09-01), Zamora
patent: 5670617 (1997-09-01), Frankel et al.
patent: 5674980 (1997-10-01), Frankel et al.
patent: 5747641 (1998-05-01), Pabo et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5846743 (1998-12-01), Janmey et al.
patent: 6348185 (2002-02-01), Piwnica-Worms
patent: 6589503 (2003-07-01), Piwnica-Worms
patent: 7306783 (2007-12-01), Piwnica-Worms
patent: 7306784 (2007-12-01), Piwnica-Worms
patent: 7435716 (2008-10-01), Ofek et al.
patent: 2003/0219375 (2003-11-01), Piwnica-Worms
patent: 2094658 (1993-10-01), None
patent: 0213523 (1987-03-01), None
patent: 0359347 (1990-03-01), None
patent: 06182227 (1994-10-01), None
patent: WO 91/09958 (1991-07-01), None
patent: WO 94/04686 (1994-03-01), None
patent: WO 98/52614 (1998-11-01), None
patent: WO 99/09056 (1999-02-01), None
patent: WO 99/67284 (1999-12-01), None
patent: WO 01/82975 (2001-11-01), None
U.S. Appl. No. 60/082,402, filed Apr. 20, 1998.
U.S. Appl. No. 60/111,701, filed Dec. 10, 1998.
U.S. Appl. No. 60/122,757, filed Feb. 28, 1999.
Akiyama et al., “Isolation and Genetic Characterization of Human KB Cell Lines Resistant to Multiple Drugs,” Somatic Cell and Molecular Genetics, 1985, pp. 117-126, vol. 11.
Albericio et al., “Use of Onium Salt-Based Coupling Reagents in Peptide Synthesis,” J. Org. Chem., 1998, pp. 9678-9683, vol. 63.
Anderson et al., “Tumor Cell Retention of Antibody Fab Fragments is Enhanced by an Attached HIV Tat Protein-Derived Peptide,” Biochem. Biophys. Res. Comm., 1993, pp. 876-884, vol. 194.
Arano et al., “Chemical Design of Radiolabeled Antibody Fragments for Low Renal Radioactivity Levels,” Cancer Res., 1999, pp. 128-134, vol. 39.
Arpicco et al., “New Coupling Reagents for the Preparation of Disulfide Cross-Linked Conjugates with Increased Stability,” Bioconjugate Chem., 1997, pp. 327-337, vol. 8.
Ashkenazi et al., “Death Receptors: Signaling and Modulation,” Science, 1998, pp. 1305-1308, vol. 281.
Avrameas et al., “Polyreactive anti-DNA Monoclonal Antibodies and a Derived Peptide as Vectors for the Intracytoplasmic and Intranuclear Translocation of Macromolecules,” Proc. Natl. Acad. Sci. USA, 1998, pp. 5601-5606, vol. 95.
Babich et al., “Effect of “Co-ligand” on the Biodistribution of99mTc-labeled Hydrazino Nicotinic Acid Derivatized Chemotactic Peptides,” Nucl. Med. Biol., 1995, pp. 25-30, vol. 22.
Baum et al., “Initial Clinical Results with Technetium-99m-Labeled LL2 Monoclonal Antibody Fragment in the Radioimmunodetection of B-Cell Lymphomas,” Cancer, 1994, pp. 896-899, vol. 73.
Behr et al., “Comparison of Complete Versus Fragmented Technetium-99m-Labeled Anti-CEA Monoclonal Antibodies for Immunoscintigraphy in Colorectal Cancer,” J. Nuclear Med., 1995, pp. 430-441, vol. 36.
Beyer et al., “Synthesis and in Vitro Efficacy of Transferrin Conjugates of the Anticancer Drug Chlorambucil,” J. Med. Chem., 1998, pp. 2701-2708, vol. 41.
Blankenberg et al., “In Vivo Detection and Imaging of Phosphatidylserine Expression During Programmed Cell Death,” Proc. Natl. Acad. Sci. USA, 1998, pp. 6349-6354, vol. 95.
Blomberg et al., “Terbium and Rhodamine as Labels in a Homogeneous Time—Resolved Fluorometric Energy Transfer Assay of the β Subunit of Human Chorionic Gonadotropin in Serum,” Clinical Chem., 1999, pp. 855-861, vol. 45.
Bosch et al., “Characterization of Functional Assays of Multidrug Resistance P-Glycoprotein Transport Activity,” Leukemia, 1997, pp. 1131-1137, vol. 11.
Buijs et al., “Dosimetric Evaluation of Immunoscintigraphy Using Indium-111-Labeled Monoclonal Antibody Fragments in Patients with Ovarian Cancer,” J. Nuclear Med., 1992, pp. 1113-1120, vol. 33.
Choi et al., “Bodistribution of18F- and125I-Labeled Anti-Tac Disulfide-Stabilized Fv Fragments in Nude Mice with Interleukin 2α Receptor-Positive Tumor Xenografts,” Cancer Res., 1995, pp. 5323-5329, vol. 55.
Deguchi et al., “Retention of Biologic Activity of Human Epidermal Growth Factor Following Conjugation to a Blood-Brain Barrier Drug Delivery Vector Via an Extended Poly(ethylene glycol) Linker,” Bio. Chem., 1999, pp. 32-37, vol. 10.
Derossi et al., “Trojan Peptides: The Penetratin System for Intracellular Delivery,” Cell Biol., 1998, pp. 84-87, vol. 8.
Derossi et al., “Cell Internalization of the Third Helix of the Antennapedia Homeodomain is Receptor-Independent,” J. Biol. Chem., 1996, pp. 18188-18193, vol. 271.
Dirven et al., “Glutathione Conjugation of Alkylating Cytostatic Drugs with a Nitrogen Mustard Group and the Roleof Glutathion S-Transferases,” Chem. Res. Toxicol., 1996, pp. 351-360, vol. 9.
Dischino et al., “Relationship Between Lipophilicity and Brain Extraction of C-11-Labeled Radiopharmaceuticals,” J. Nuclear Medicine, 1983, pp. 1030-1038, vol. 24.
Drouillat et al., “Novel Liposaccharide Conjugates for Drug and Peptide Delivery,” J. Pharm. Sci., 1998, pp. 25-30, vol. 87.
Eckelman, “Radiolabeling with Technetium-99m to Study High-Capacity and Low-Capacity Biochemical Systems,” European J. Nuclear Med., 1995, pp. 249-263, vol. 22.
Efthymiadis et al., “The HIV-1 Tat Nuclear Localization Sequence Confers Nuclear Import Properties,” J. Biol. Chem., 1998, pp. 1623-1628, vol. 273.
Elliott et al., “Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,” Cell, 1997, pp. 223-233, vol. 88.
Enari et al., “Sequential Activation of ICE-like and CPP32-like Proteases During Fas-Mediated Apoptosis,” Nature, 1996, pp. 723-726, vol. 380.
Engelstad et al., “Contrast Agents,” Introduction, pp. 161-181, Chapter 9.
Evan et al., “A Matter of Life and Cell Death,” Science, 1998, pp. 1317-1322, vol. 281.
Fahraeus et al., “Inhibition of pRb phosphorylatoin and Cell-Cycle Progression by a 20-Residue Peptide Derived from p16CDKN2/INK4A,” Current Biology, 1996, pp. 84-91, vol. 6.
Fawell et al., “Tat-Mediated Delivery of Heterologous Proteins in Cells,” Proc. Natl. Acad. Sci. USA, 1994, pp. 664-668, vol. 91.
Fernandes-Alnemri et al., “In Vitro Activation of CPP32 and Mch3 by Mch4, a Novel Human Cysteine Protease Containing Two FADD-like Domains,” Proc. Natl. Acad. Sci. USA, 1996, pp. 7464-7469, vol. 93.
Fisher, “Apoptosis in Cancer Therapy: Crossing the Threshold,” Cell, 1994, pp. 539-542, vol. 78.
Frankel et al., “Cellular Uptake of the Tat Protein from Human Immunodeficiency Virus,” Cell, 1988, pp. 1189-1193, vol. 55.
Frisch et al., “Synthesis of Short Polyoxyethylene-Based Heterobifunctional Cross-Linking Reagents. Application to the Coupling of Peptides to Liposomes,” Bioconjugate Chem., 1996, pp. 180-186, vol. 7.
Fulda et al.,“The CD95 (APO-1Fas) System Mediates Drug-Induced Apoptosis in Neuroblastoma Cells,” Cancer Res., 1997, pp. 3823-3829, vol. 57.
Fuller, “The Steroid Receptor Superfamily: Mechanisms of Diversity,” FASEB J., 1991, pp. 3092-3099, vol. 5.
Garcia et al., “Functional Domains Required for Tat-Induced Transcriptional Activation of the HIV-1 Long Terminal Repeat,” The EMBO J., 1988, pp. 3143-3147, vol. 7.
Green et al., “Mitochondria and Apoptosis,” Science, 1998, pp. 1309-1312, vol. 281.
Grummon et al., Syn

Affiliated with

Also associated with

Rating

Membrane-permeant peptide complexes for treatment of sepsis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Membrane-permeant peptide complexes for treatment of sepsis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Membrane-permeant peptide complexes for treatment of sepsis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4274425